GlassScriptPhysician profile
Tirsa C Quartullo
NPI 1467455477
$31,224.15
in general payments reported to CMS, 2019-2025
30 companies · $2,493 in 2025
The $2,493 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17K · 2022: $4,297 · 2023: $4,304 · 2024: $2,678 · 2025: $2,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,154 · Education: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,153.98 |
| Education | $320.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13,167.51 | 2021-2025 | |
| Amgen INC. | $2,935.09 | 2021-2025 | Otezla, Otezla, Enbrel |
| Genzyme Corporation | $2,457.29 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,514.90 | 2021-2025 | Odomzo, Blu-U, Ilumya |
| Novartis Pharmaceuticals Corporation | $1,401.41 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $1,368.96 | 2021-2024 | Dupixent |
| Janssen Biotech, INC. | $1,253.89 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Leo Pharma INC. | $932.33 | 2021-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $867.12 | 2021-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $747.15 | 2021-2024 | Siliq, Targretin |
| Lilly USA, LLC | $703.42 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $678.33 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $639.10 | 2021-2025 | |
| Dermavant Sciences, INC. | $606.47 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $345.01 | 2022-2024 | Sotyktu |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $308.45 | 2021 | |
| Incyte Corporation | $282.83 | 2021-2025 | Opzelura |
| Genentech USA, INC. | $280.00 | 2021-2023 | Xolair |
| Arcutis Biotherapeutics, INC. | $257.75 | 2023-2025 | Zoryve |
| Allergan, INC. | $124.92 | 2022 | |
| Biofrontera INC. | $77.01 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $63.27 | 2023-2025 | Hadlima, Vtama |
| Sanofi-Aventis U.S. LLC | $46.53 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.91 | 2023 | Spevigo |
| Botanix Sb INC | $30.29 | 2025 | Sofdra |
| Almirall LLC | $28.98 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $24.33 | 2021 | |
| Kyowa Kirin, INC. | $23.07 | 2023 | Poteligeo |
| Strata Skin Sciences, INC. | $16.94 | 2024 | Xtrac |
| Mayne Pharma Commercial LLC | $9.89 | 2023-2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tirsa Quartullo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.